Dispensing Hydromorphone Contin 3 mg BID
Yes, for hydromorphone Contin 3 mg twice daily, you should dispense 60 tablets for a 30-day supply each month (2 tablets per day × 30 days = 60 tablets).
Standard Dispensing Practice
For controlled-release opioid formulations like hydromorphone Contin prescribed at twice-daily dosing:
- Calculation: 3 mg BID = 2 tablets daily
- 30-day supply: 60 tablets total
- Monthly refills: Standard practice for chronic opioid therapy
This aligns with established guidelines for modified-release opioid formulations, which are designed for 12-hourly administration 1. The evidence consistently supports that controlled-release formulations should not be given more frequently than every 12 hours, making twice-daily dosing the standard regimen 2.
Key Dispensing Considerations
Regulatory compliance: Most jurisdictions require monthly dispensing of controlled substances like hydromorphone, with prescriptions typically written for 30-day supplies. This practice:
- Ensures regular patient monitoring
- Allows dose reassessment at appropriate intervals
- Maintains compliance with controlled substance regulations
- Facilitates ongoing evaluation of pain control and adverse effects
Clinical monitoring: The 30-day dispensing interval is clinically appropriate because steady-state plasma concentrations are reached within 24 hours of starting or adjusting opioid therapy 2. Monthly follow-up allows adequate time to assess:
- Efficacy of current dose
- Need for breakthrough medication
- Presence of adverse effects
- Signs of tolerance or dose escalation needs
Important Caveats
Breakthrough pain management: Patients on controlled-release hydromorphone should have access to immediate-release opioid rescue doses. For a patient on 6 mg total daily dose of hydromorphone Contin (3 mg BID), the appropriate breakthrough dose would be approximately one-third of the 12-hourly dose, or roughly 1 mg of immediate-release hydromorphone 2.
Dose stability requirement: The 30-day supply assumes the patient is on a stable maintenance dose. During initial titration phases, shorter dispensing intervals may be more appropriate to allow for dose adjustments 1.